This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Children are not little adults. This oft-repeated mantra implies that to study the safety and efficacy as well as the pharmacokinetics of drugs in children, it is not sufficient to simply extrapolate adult data. This is the position of the American Academy of Pediatrics. Moreover, the Food and Drug Administration (FDA) grants approval for drugs based on the populations in which they were studied. In partial seizures in older children, one can usually presume that drugs effective in adults with partial seizures will also be effective in children, although the safety and pharmacokinetics will be different as noted in a National Institute of Neurologic Disorders and Stroke consensus conference on the development of new antiepileptic drugs (AEDs) in children.1 In neonates and infants, no such assumptions can be made.1,2 Yet despite financial incentives to pharmaceutical manufacturers in the form of additional patent exclusivity period on a product, there are few drugs (and in particular, few AEDs) that have obtained a pediatric indication, particularly in infants and younger children. The study of oxcarbazepine in very young children by Piña-Garza et al.3 in this issue of Neurology is a welcome addition and illustrates many of the advantages as well as the difficulties of doing pediatric drug trials.
Why are so few good quality randomized clinical trials of newer AEDs being done in children? Historically, new AEDs were studied primarily in adult males. Recent FDA …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
